Page 337 - Read Online

Egresi et al. Hepatoma Res 2016;2:328-30 Hepatoma Research
DOI: 10.20517/2394-5079.2016.31
www.hrjournal.net
Commentary Open Access

Comments on “The severity of non-alcoholic

fatty liver disease is associated with gut

dysbiosis and shift in the metabolic function

of the gut microbiota”

Anna Egresi, Krisztina Hagymási, Gabriella Lengyel
The 2nd Department of Internal Medicine, Semmelweis University, H-1088 Budapest, Hungary

Correspondence to: Dr. Gabriella Lengyel, the 2nd Department of Internal Medicine, Semmelweis University, Szentkirályi Street 46, H-1088 Budapest,
Hungary. E-mail: lengyel.gabriella@med.semmelweis-univ.hu

How to cite this article: Egresi A, Hagymási K, Lengyel G. Comments on “The severity of non-alcoholic fatty liver disease is associated with gut
dysbiosis and shift in the metabolic function of the gut microbiota”. Hepatoma Res 2016;2:328-30.
Article history: Received: 20-07-2016 Accepted: 25-11-2016 Published: 13-12-2016

“Boursier J, Mueller O, Barret M, Machado M, metabolic syndrome, diabetes, and cardiovascular
[3]
Fizanne L, Araujo-Perez F, Guy CD, Seed PC, Rawls diseases. Gut dysbiosis, especially the microbial
JF, David LA, Hunault G, Oberti F, Calès P, Diehl translocation and their products such as endotoxin
AM. The severity of nonalcoholic fatty liver disease (lipopolysaccharides) across the intestinal gut
is associated with gut dysbiosis and shift in the barrier is highly investigated in patients with chronic
[4]
metabolic function of the gut microbiota. Hepatology liver diseases. Besides that, gut microbiota may
2016;63:764-75.” influence the pathogenesis of NAFLD by increased
production and absorption of gut short-chain fatty
Non-alcoholic fatty liver disease (NAFLD) has a rising acids; changes in dietary choline metabolism; altered
prevalence worldwide. It is characterized with lipid bile acid pools; increased production of microbiota-
deposition in hepatocytes that is unrelated to alcohol derived endogenous ethanol; and interaction
[5]
consumption. Insulin resistance and oxidative damage between dietary factors and microbiota. Nowadays
plays a key role in its pathogenesis. NAFLD is a there is no evidence-based, effective therapy of
[1]
complex disease, classified in simple steatosis (SS) NAFLD. Current therapy for NAFLD includes lifestyle
and non-alcoholic steatohepatitis (NASH). Lifestyle interventions, medical treatment (e.g. antioxidants,
changes and treatment of hyperinsulinaemia could oral hypoglycaemic agents, and lipid-lowering
reverse SS. However, 20-30% of NAFLD patients agents), and bariatric surgery. Lately, probiotics have
develop to NASH, which could lead to liver fibrosis, been discussed as a potential treatment of NAFLD. [6]
[2]
cirrhosis and cancer.
Boursier et al. present a remarkable study about
[7]
Recently, the intestinal microbial flora has gained the analysis of composition of gut microbiota of stool
great attention in various diseases, such as obesity, samples from patients affected by this disease.
Quick Response Code:
This is an open access article distributed under the terms of the Creative Commons Attribution-
NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work
non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

For reprints contact: service@oaepublish.com

328 © 2016 OAE Publishing Inc. www.oaepublish.com